VTD方案治疗多发性骨髓瘤  

VTD Regimen Therapy for Multiple Myeloma

作　　者：杨国华[1] 沈云峰[1] 钱锡峰[1] 程枫[1] 

机构地区：[1]江苏省无锡市人民医院血液科,无锡214023

出　　处：《中国医药导刊》2009年第11期1829-1830,共2页Chinese Journal of Medicinal Guide

摘　　要：目的:观察VTD方案治疗初治及复发难治多发性骨髓瘤(MM)的疗效及不良反应。方法:21例患者均采用硼替佐米(1.3mg/m^2,第1、4、8、11d)联合沙利度胺(200mg/d)及地塞米松(20mg/d,d1～d4,d8～d11)治疗,21天为一疗程。每例患者分别接受了1～4个疗程的治疗。结果:总有效率(ORR)为76.2%,其中初治组ORR为100%,复发难治组ORR为58.3%。CR 2例(9.5%)、nCR 3例(14.3%)、PR 8例(38.1%)、MCR3例(14.3%)。不良反应较轻,主要为乏力、血液学毒性、胃肠道反应、周围神经毒性,经对症治疗后缓解。结论:VTD方案治疗初治及复发难治MM患者具有有效率高,耐受性好,特别是在伴有肾功能不全患者中疗效可靠、安全。Objective：To investigate the efficacy and toxicity of VTD regimen for the treatment of patients with newly diagnosed and relapsed refractory multiple myeloma（MM）.Methods：Twenty-one patients were treated with bortezomib 1.3mg/m^2 on days 1,4,8 and 11,along with thalidomide 200mg/d continuously and dexamethasone 20mg on days 1-4,8-11.with 21 days as a cycle.The patients had received one to four cousrse at least.Results：The overall response rate（ORR） to VTD regimen was 76.2%,and was 100% in newly diagnosed patients and 58.3% in relapsed refractory patients,including complete response in 2 （9.5%）,near complete response in 3 （14.3%）,partial response in 8 （38.1%） and minimal response in 3 （14.3%）.The main side reactions were fatigue,haematologic,gastrointestinsl andperipheral neuropathic.The adverse events were subsided on routine supportive care.Conelusions：VTD regimen is an effective therapy with a high response rate manageable toxicities for patients with newly diagnosed and relapsed refractory multiple myeloma.even in paients with renal insufficiency.

关 键 词：多发性骨髓瘤 硼替佐米 沙利度胺 地塞米松 治疗结果 

分 类 号：R733.3[医药卫生—肿瘤]